Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.1.108 (
TAT
)
2,389
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The mechanisms for regulating
PIKfyve
complex activity are currently emerging. The
PIKfyve
complex, consisting of the phosphoinositide kinase
PIKfyve
(also known as
FAB1
), VAC14 and FIG4, is required for the production of phosphatidylinositol 3,5-bisphosphate [PI(3,5)P2].
PIKfyve
function is required for homoeostasis of the endo/lysosomal system and is crucially implicated in neuronal function and integrity, as loss of function mutations in the
PIKfyve
complex lead to neurodegeneration in mouse models and human patients. Our recent work has shown that the intracellular domain of the amyloid precursor protein (APP), a molecule central to the aetiology of Alzheimer's disease binds to VAC14 and enhances
PIKfyve
function. In the present study, we utilize this recent advance to create an easy-to-use tool for increasing
PIKfyve
activity in cells. We fused APP intracellular domain (AICD) to the HIV
TAT
domain, a cell-permeable peptide allowing proteins to penetrate cells. The resultant
TAT
-AICD fusion protein is cell permeable and triggers an increase in PI(3,5)P2 Using the PI(3,5)P2 specific GFP-ML1Nx2 probe, we show that cell-permeable AICD alters PI(3,5)P2 dynamics.
TAT
-AICD also provides partial protection from pharmacological inhibition of
PIKfyve
. All three lines of evidence show that the AICD activates the
PIKfyve
complex in cells, a finding that is important for our understanding of the mechanism of neurodegeneration in Alzheimer's disease.
...
PMID:A cell-permeable tool for analysing APP intracellular domain function and manipulation of PIKfyve activity. 2693 81